Exchange: NASDAQ·Updated 07:30 PM EDT

LIVN News

News
all
press releases
LivaNova to Announce Third-Quarter 2026 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the...
Business Wire
LivaNova to Announce Third-Quarter 2026 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the...
Business Wire
More News
LivaNova Director Sells 1,650 Shares for $131,500
Key PointsThe sale was valued at approximately $131,500...
Nasdaq News: Markets
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City: Morgan Stanley 24th Annual Global Healthcare Conference on Mon., Sept. 14, from 11:30 a.m.-12:05 p.m. EDT Baird 2026...
Business Wire
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
Zacks
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
Zacks
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
Zacks
Ahmet Tezel Executes Sell Order: Offloads $876K In LivaNova Stock
A substantial insider sell was reported on August 13, by Ahmet Tezel, Chief Innovation Officer at LivaNova (NASDAQ:LIVN), based on the recent SEC filing. What Happened: Tezel's recent Form 4 filing with the U.S.read more...
Benzinga
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova (LIVN) Q2 2026 Earnings Call Transcript...
Yahoo! Finance: News
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
Zacks
INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease
Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.
Zacks

Advertisement|Remove ads.